OBjECTivES
• To identify baseline demographics and clinical characteristics associated with all-cause and ASCVD-related healthcare costs at 12 months following initial diagnosis of ASCVD in patients not previously treated for hyperlipidemia.
CONCLUSiONS
• As expected, age, gender, baseline comorbid conditions, baseline use of specific medications, baseline lipid profiles, and type of index ASCVD were significantly associated with all-cause and ASCVD-related healthcare costs.
• Geographic location and health insurance type also played a significant role in healthcare costs among ASCVD patients.
LiMiTATiONS
• Due to the nature of claims data, the specificity of identifying true ASCVD-related costs may be limited.
• Multivariable analyses were restricted to patients with available lab data. Results may not be generalizable to all patients in the HIRD SM , or to patients in non-commercial health plans or without any health insurance.
• Some patient characteristics that may be expected to affect costs are not available in claims data (family history, smoking status, diet, exercise, etc.).
Presented at the ISPOR 
Patient Identification
• Patients with ASCVD were identified during the intake period of 01/01/2007 to 11/30/2012 based on the presence of an ASCVD diagnosis defined as either: -≥1 inpatient or emergency room (ER) visit with any ASCVD ICD-9-CM diagnosis codes in the primary diagnosis position or -≥2 outpatient or physician office visits that were ≥30 days apart with ASCVD ICD-9-CM diagnosis codes within the same ASCVD group (specified in Table 1 ).
• The earliest medical claim for an inpatient, ER, or outpatient encounter qualifying as an ASCVD diagnosis within the intake period was defined as index date.
Inclusion Criteria
• Patients aged ≥18 years on index date.
• Patients enrolled in only commercial or Medicare Advantage plans during the study period.
• Patients with ≥12 months pre-and ≥12 months post-index continuous health plan enrollment.
Exclusion Criteria
• Patients with ≥1 ASCVD claim in the 12 month pre-index period.
• Patients with ≥1 claim for a lipid-lowering medication (LLM) during the 12-month pre-index period. Table 2) • 128,017 ASCVD patients were identified with a mean (SD, median) age of 59 (13, 58) years; 43.1% were female.
• 21.0% of all patients had ACS as their index ASCVD diagnosis.
Table 2. Baseline Demographic and Clinical Characteristics of ASCVD Patients

All-cAuse And AscVd-relAted HeAltHcAre costs
• Among all patients, baseline mean (SD, median) all-cause costs were $8,852 ($25,608, $3,379).
• At 12 months follow-up, mean (SD, median) all-cause costs for all patients were $31,443
($54,040, $15,389) while ASCVD-related costs were $20,289 ($45,159, $4,510).
BAseline FActors AssociAted witH All-cAuse And AscVd-relAted HeAltHcAre costs At 12 MontHs Follow-up
• There were 26,388 and 26,376 patients included in the regression models for all-cause and ASCVD-related healthcare costs, respectively, after excluding patients without available baseline lipid values or with zero all-cause/ASCVD-related costs at follow-up.
• The following factors were positively associated with all-cause healthcare costs at 12 months follow-up (p<0.05) (see Figure 1) : -Older age, plan region including South and West (vs. Midwest); -Higher QCI, index ACS, index ACD, baseline depression, pain, obesity, and chronic kidney disease; -Baseline use of antihypertensive agents, antidiabetic medications, and digoxin; -Higher baseline all-cause healthcare costs (in thousands).
• The following factors were negatively associated with all-cause healthcare costs at 12 months follow-up (p<0.05) (see Figure 1 ): -Female, Northeast plan (vs. Midwest), HMO (vs. PPO), Medicare Advantage Plans; -Index CHD, index PAD, baseline dyslipidemia; -Baseline goal attainment of LDL-C (<100 mg/dL), HDL-C (>40/50 mg/dL for males/females, triglycerides (<150 mg/dL), and total cholesterol level (<200 mg/dL).
• Similar findings were reported for ASCVD-related healthcare costs at 12 months follow-up (see Figure 2) . • All-cause (at baseline and 12 months follow-up) and ASCVD-related (at 12 months follow-up) healthcare costs included the combined amount paid by both health plan and patient for all-cause and ASCVD-related inpatient hospitalizations, ER visits, physician office visits, other outpatient visits/services, and pharmacy prescriptions.
• ASCVD-related costs were measured by summing costs from medical claims with any ICD-9-CM diagnosis codes for ASCVD and costs from pharmacy claims for ASCVD-related medications at 12 months follow-up.
• Costs were adjusted to 2013 dollar values based on the consumer price index for medical care from the U.S. Bureau of Labor Statistics.
STATISTICAL ANALYSES
• Descriptive statistics including means (standard deviation [SD] and median) and absolute/ relative frequencies for continuous and categorical data, respectively, were reported.
• Generalized linear models with gamma distribution and log link were used to examine baseline factors associated with 12 month follow-up all-cause and ASCVD-related healthcare costs. 
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